CBDV shows excellent promise as a treatment for digestive disorders. Pharmaceuticals have even patented a drug containing THCV, CBG, and CBC to treat Crohn’s disease and other gastrointestinal problems.
CBDV has been shown to inhibit the activity of specific nerve cells involved in inflammation, seizures, pain, and other conditions. Numerous illnesses and ailments, such as pediatric intractable epilepsy, can benefit from lessening their symptoms. But because it is rare, some people are still unaware and want to highlight what is CBDV and how it functions in the body.
Studies have found that CBDV is a potent inhibitor of the receptors that promote the growth and spread of cancerous tumors. It works by blocking the receptors that interact with L-a-lysophosphatidylinositol (LPI), which is known to cause cancer cell proliferation and metastasis.
Another benefit of CBDV is that it acts as a natural anti-nausea agent. It does this by acting as an agonist on CB1 receptors, thereby blocking the nausea response in the brain. This can be beneficial for people suffering from a variety of medical conditions, including chronic nausea.
The human body produces endocannabinoids (endogenous, lipid-based retrograde neurotransmitters) that bind to cannabinoid receptors and trigger specific effects. Two cannabinoid receptors, CB1 and CB2, and the biosynthetic enzymes fatty acid amide hydrolase (FAAH) and monoacylglycerol lipase (MAGL) comprise the canonical endocannabinoid system. THC and CBD also bind to these receptors and have their unique effects.
Unlike most neurotransmitters, which are stored in vesicles and released on demand, endocannabinoids are formed on the spot and act pre-synaptically. For example, in response to a glutamate surge, the post-synaptic cell releases an endocannabinoid that travels across the synapse and binds with the CB1 receptor on the sending cell to inhibit excessive excitatory activity. This mechanism fine-tunes synaptic transmission and maintains homeostasis. Research suggests that many medical conditions occur when there is a shortage or imbalance of endocannabinoids, called clinical endocannabinoid deficiency (CED). Fortunately, everything from exercise to fasting to certain herbs can help increase endocannabinoid levels.
The GABA system controls the brain’s inhibitory and excitatory functions. CBDV also interacts with this system, and a 2019 study found that it impacts glutamate and GABA metabolites in healthy participants and those with an autism spectrum disorder. This suggests CBD could be useful for psychiatric conditions, including anxiety and depression.
CBDV has a long side chain, which increases its binding affinity to CB receptors over short-chain cannabinoids like CBD. This may help to reduce a lot of the hyperexcitability seen in epilepsy and other neurological disorders.
CBDV also appears to desensitize the TRPV1 and TRPA1 ion channels that play an essential role in pain and inflammation. Its anti-inflammatory qualities are probably due in large part to this.
As the second most abundant neurotransmitter in the brain, serotonin regulates several physiological processes. It acts pro- and anti-analgesic, reduces anxiety and depression, and boosts mood. Serotonin also regulates food movement through the gastrointestinal tract and helps with pain perception, digestion, and energy balance.
CBDV has been shown to affect the Serotonin Receptors (TRP) significantly. Studies done in mice that mimic Rett Syndrome showed CBDV substantially improves health and motor coordination and normalizes excess brain weight. It was also able to enhance sociability deficits and reduce gastrointestinal inflammation.
A study tested THCV and CBDV on animal models with toxin-induced nausea. The results indicated that THCV and CBDV worked as CB1 receptor inverse agonists, suppressing the nausea response.
Studies show that CBDV may be helpful in various conditions, including autism spectrum disorders, seizures, and anxiety.